GlassScriptPhysician profile
Matthew Bruno
NPI 1104854066
$17,238.89
in general payments reported to CMS, 2019-2025
9 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,550 · 2023: $220 · 2024: $2,832 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,063 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,513 · Food and Beverage: $855 · Travel and Lodging: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,062.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,512.50 |
| Food and Beverage | $854.60 |
| Travel and Lodging | $258.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $13,037.45 | 2024-2025 | Anzupgo, Adbry |
| Epi Health, LLC | $2,550.00 | 2022 | |
| Abbvie INC. | $1,200.00 | 2024 | |
| Amgen INC. | $134.18 | 2023 | Otezla |
| Genzyme Corporation | $109.78 | 2024 | |
| Ucb, INC. | $85.51 | 2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $72.63 | 2024 | |
| Arcutis Biotherapeutics, INC. | $30.93 | 2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $18.41 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.